{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T02:43:33Z","timestamp":1789353813873,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunobiology"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.imbio.2013.05.006","type":"journal-article","created":{"date-parts":[[2013,5,30]],"date-time":"2013-05-30T13:30:44Z","timestamp":1369920644000},"page":"1524-1528","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Enhancement of humoral and cellular immune responses by monophosphoryl lipid A (MPLA) as an adjuvant to the rabies vaccine in BALB\/c mice"],"prefix":"10.1016","volume":"218","author":[{"given":"Xiaobo","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naishuo","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.imbio.2013.05.006_bib0005","doi-asserted-by":"crossref","first-page":"5922","DOI":"10.1016\/j.vaccine.2008.08.050","article-title":"First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity","volume":"26","author":"Bakker","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.imbio.2013.05.006_bib0010","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1006\/rtph.2002.1541","article-title":"Safety evaluation of monophosphoryl lipid A (MPL): an immunostimulatory adjuvant","volume":"35","author":"Baldrick","year":"2002","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.imbio.2013.05.006_bib0015","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1517\/14712598.4.7.1129","article-title":"Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents","volume":"4","author":"Baldridge","year":"2004","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.imbio.2013.05.006_bib0020","doi-asserted-by":"crossref","first-page":"6448","DOI":"10.4049\/jimmunol.163.12.6448","article-title":"Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling","volume":"163","author":"Brewer","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.imbio.2013.05.006_bib0025","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0147-9571(87)90033-6","article-title":"Experimental rabies in skunks: immune response and salivary gland infection","volume":"10","author":"Charlton","year":"1987","journal-title":"Comp Immunol Microbiol Infect Dis"},{"key":"10.1016\/j.imbio.2013.05.006_bib0030","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/intimm\/12.6.807","article-title":"The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells","volume":"12","author":"De Becker","year":"2000","journal-title":"Int Immunol"},{"key":"10.1016\/j.imbio.2013.05.006_bib0035","doi-asserted-by":"crossref","first-page":"6186","DOI":"10.4049\/jimmunol.0901474","article-title":"AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity","volume":"183","author":"Didierlaurent","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.imbio.2013.05.006_bib0040","doi-asserted-by":"crossref","first-page":"e515","DOI":"10.1371\/journal.pntd.0000515","article-title":"Novel vaccines to human rabies","volume":"3","author":"Ertl","year":"2009","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.imbio.2013.05.006_bib0045","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1586\/14760584.2.2.219","article-title":"Enhancement of antigen-specific immunity via the TLR4 ligands MPL adjuvant and Ribi.529","volume":"2","author":"Evans","year":"2003","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.imbio.2013.05.006_bib0050","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/nrd3426","article-title":"Vaccines: nano-adjuvant: double TLR stimulation is the key","volume":"10","author":"Flemming","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.imbio.2013.05.006_bib0055","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1586\/erv.11.29","article-title":"Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems","volume":"10","author":"Garcon","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.imbio.2013.05.006_bib0060","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1474-4422(02)00041-8","article-title":"Human rabies: a disease of complex neuropathogenetic mechanisms and diagnostic challenges","volume":"1","author":"Hemachudha","year":"2002","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.imbio.2013.05.006_bib0065","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nature09737","article-title":"Programming the magnitude and persistence of antibody responses with innate immunity","volume":"470","author":"Kasturi","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.imbio.2013.05.006_bib0070","doi-asserted-by":"crossref","first-page":"6777","DOI":"10.1016\/j.vaccine.2008.09.045","article-title":"Engagement of TLR signaling as adjuvant: towards smarter vaccine and beyond","volume":"26","author":"Lahiri","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.imbio.2013.05.006_bib0075","doi-asserted-by":"crossref","first-page":"8639","DOI":"10.1128\/JVI.00596-10","article-title":"An adjuvant for the induction of potent, protective humoral responses to an H5N1 influenza virus vaccine with antigen-sparing effect in mice","volume":"84","author":"Lau","year":"2010","journal-title":"J Virol"},{"key":"10.1016\/j.imbio.2013.05.006_bib0080","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.vaccine.2008.12.048","article-title":"A TLR3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic","volume":"27","author":"Lau","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.imbio.2013.05.006_bib0085","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.0818-9641.2004.01286.x","article-title":"Aluminium compounds for use in vaccines","volume":"82","author":"Lindblad","year":"2004","journal-title":"Immunol Cell Biol"},{"key":"10.1016\/j.imbio.2013.05.006_bib0090","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.ijbiomac.2012.01.035","article-title":"Adjuvant activity of Chinese herbal polysaccharides in inactivated veterinary rabies vaccines","volume":"50","author":"Liu","year":"2012","journal-title":"Int J Biol Macromol"},{"key":"10.1016\/j.imbio.2013.05.006_bib0095","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0264-410X(99)00352-7","article-title":"DNA vaccination of mice against rabies virus: effects of the route of vaccination and the adjuvant monophosphoryl lipid A (MPL)","volume":"18","author":"Lodmell","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.imbio.2013.05.006_bib0100","first-page":"1","article-title":"Human rabies prevention\u2014United States, 2008: recommendations of the Advisory Committee on Immunization Practices","volume":"57","author":"Manning","year":"2008","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.imbio.2013.05.006_bib0105","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1016\/S0264-410X(99)00062-6","article-title":"The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1","volume":"17","author":"Moore","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.imbio.2013.05.006_bib0110","first-page":"33","article-title":"Pathogenesis of skunk rabies virus: quantitation in skunks and foxes","volume":"27","author":"Parker","year":"1966","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.imbio.2013.05.006_bib0115","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1021\/mp2002494","article-title":"Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route","volume":"9","author":"Ravindran","year":"2012","journal-title":"Mol Pharm"},{"key":"10.1016\/j.imbio.2013.05.006_bib0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2005.01.006","article-title":"Transcriptional signaling by double-stranded RNA: role of TLR3","volume":"16","author":"Sen","year":"2005","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.imbio.2013.05.006_bib0125","first-page":"113","article-title":"PIKA as an adjuvant enhances specific humoral and cellular immune responses following the vaccination of mice with HBsAg plus PIKA","volume":"4","author":"Shen","year":"2007","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.imbio.2013.05.006_bib0130","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJM199101243240401","article-title":"Unexplained rabies in three immigrants in the United States. A virologic investigation","volume":"324","author":"Smith","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.imbio.2013.05.006_bib0135","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1056\/NEJM199701093360202","article-title":"A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group","volume":"336","author":"Stoute","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.imbio.2013.05.006_bib0140","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s00262-010-0843-z","article-title":"Monophosphoryl lipid A plus IFNgamma maturation of dendritic cells induces antigen-specific CD8+ cytotoxic T cells with high cytolytic potential","volume":"59","author":"Ten","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.imbio.2013.05.006_bib0145","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S0264-410X(97)00254-5","article-title":"Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system","volume":"16","author":"Thoelen","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.imbio.2013.05.006_bib0150","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1189\/jlb.0305172","article-title":"The low-toxicity versions of LPS, MPL adjuvant and RC529, are efficient adjuvants for CD4+ T cells","volume":"78","author":"Thompson","year":"2005","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.imbio.2013.05.006_bib0155","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/S0264-410X(98)00088-7","article-title":"Enhanced immunogenicity of a recombinant genital warts vaccine adjuvanted with monophosphoryl lipid A","volume":"16","author":"Thompson","year":"1998","journal-title":"Vaccine"},{"key":"10.1016\/j.imbio.2013.05.006_bib0160","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/978-1-4615-1823-5_21","article-title":"Monophosphoryl lipid A as an adjuvant. Past experiences and new directions","volume":"6","author":"Ulrich","year":"1995","journal-title":"Pharm Biotechnol"},{"key":"10.1016\/j.imbio.2013.05.006_bib0165","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1016\/S0264-410X(02)00413-9","article-title":"Effect of monophosphoryl lipid A (MPL) on T-helper cells when administered as an adjuvant with pneumocococcal-CRM197 conjugate vaccine in healthy toddlers","volume":"20","author":"Vernacchio","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.imbio.2013.05.006_bib0170","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/j.vaccine.2008.01.043","article-title":"A CpG oligodeoxynucleotide acts as a potent adjuvant for inactivated rabies virus vaccine","volume":"26","author":"Wang","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.imbio.2013.05.006_bib0175","doi-asserted-by":"crossref","first-page":"e1640","DOI":"10.1371\/journal.pntd.0001640","article-title":"The spatial and temporal dynamics of rabies in China","volume":"6","author":"Yu","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.imbio.2013.05.006_bib0180","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.molimm.2012.06.014","article-title":"A human-derived protein SBP (HBsAg-binding protein) can bind to hepatitis B virus surface antigen (HBsAg) and enhance the immune response to hepatitis B virus (HBV) vaccine","volume":"53","author":"Zhang","year":"2013","journal-title":"Mol Immunol"},{"key":"10.1016\/j.imbio.2013.05.006_bib0185","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1172\/JCI39293","article-title":"Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice","volume":"120","author":"Zhu","year":"2010","journal-title":"J Clin Invest"}],"container-title":["Immunobiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0171298513001125?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0171298513001125?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T16:36:41Z","timestamp":1759250201000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0171298513001125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0171298513001125"],"URL":"https:\/\/doi.org\/10.1016\/j.imbio.2013.05.006","relation":{},"ISSN":["0171-2985"],"issn-type":[{"value":"0171-2985","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhancement of humoral and cellular immune responses by monophosphoryl lipid A (MPLA) as an adjuvant to the rabies vaccine in BALB\/c mice","name":"articletitle","label":"Article Title"},{"value":"Immunobiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imbio.2013.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier GmbH. All rights reserved.","name":"copyright","label":"Copyright"}]}}